Three Perspectives, Two Trials and One Big Goal

February 26, 2018

With more efficacy trials underway today than ever before in HIV prevention research, this episode of Px Pulse zooms in on two that have most recently launched: one of two trials testing a long-acting injectable antiretroviral called cabotegravir (HPTN 084), and the study of a "mosaic" vaccine developed by Janssen Pharmaceuticals (HVTN 705/HPX2008).

Veteran Malawian advocate Maureen Luba, Zimbabwe-based bioethicist Paul Ndebele, and leading scientist Dan Barouch each take up the subject of these trials and share their expertise on what they could mean for prevention nationally, regionally and globally.

Listen to the full podcast here (16:42)

Highlights

• Maureen Luba on what these trials could mean for Malawi, where both trials are taking place (5:04)
• Dan Barouch talks about the science of the mosaic vaccine being studied in HVTN 705/HPX 2008 (8:05)
• Paul Ndebele gives us a review of ethics standards today at trial sites (4:51)

Additional Resources

• Px Pulse: Testing Long-acting PrEP, Easier Said Than Done
• New HIV Prevention Trials Hold Promise for New Prevention Options for Women, AVAC press release
• AVAC's Introduction to Long-Acting Injectables
• Advocacy in Uncertain Times: A call to action, AVAC's report for HIV Vaccine Awareness Day 2017
• Px Wire April-June 2017 offers further details on HPTN 084 and its partner trial in men, HPTN 083
• AVAC Report 2017, Chapter 2 "Let's Get Real" provides background and perspective on the evolving standard of prevention at clinical trials

More Px Pulse

For more episodes of Px Pulse, click here.